|1.||Green, Tim P: 8 articles (07/2010 - 11/2006)|
|2.||Evans, Christopher P: 5 articles (06/2010 - 04/2008)|
|3.||Elvin, Paul: 4 articles (01/2013 - 06/2009)|
|4.||Kung, Hsing-Jien: 4 articles (06/2010 - 04/2008)|
|5.||Lara, Primo N: 3 articles (04/2009 - 04/2008)|
|6.||Gandara, David R: 3 articles (04/2009 - 04/2008)|
|7.||Kaufman, Adam C: 2 articles (06/2015 - 01/2015)|
|8.||Nygaard, Haakon B: 2 articles (06/2015 - 01/2015)|
|9.||van Dyck, Christopher H: 2 articles (06/2015 - 01/2015)|
|10.||Strittmatter, Stephen M: 2 articles (06/2015 - 01/2015)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
08/01/2015 - "Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer."
07/15/2010 - "The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking. "
08/15/2010 - "To evaluate the efficacy of saracatinib (AZD0530), an oral Src inhibitor, in colorectal cancer (CRC) and to identify biomarkers that predict antitumor activity. "
08/15/2010 - "Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer."
07/15/2010 - "Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters."
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
06/15/2009 - "Sixteen patient-derived pancreatic cancer xenografts from the PancXenoBank collection at Johns Hopkins were treated with AZD0530 (50 mg/kg/day, p.o.) for 28 days. "
04/01/2012 - "A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer."
06/15/2009 - "Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer."
11/02/2006 - "AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. "
06/15/2009 - "To determine the efficacy of AZD0530, an orally active small molecule Src inhibitor, in human pancreatic cancer xenografts and to seek biomarkers predictive of activity. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
06/15/2009 - "One gene pair (LRRC19 and IGFBP2) identified by the K-TSP classifier has high predictive power for AZD0530 sensitivity, suggesting the potential for this gene pair as biomarker for pancreatic tumor sensitivity to AZD0530."
06/15/2009 - "Three patient tumors of 16 were found to be sensitive to AZD0530, defined as tumor growth <50% compared with control tumors (100%). "
06/15/2009 - "Baseline gene expression profiles of differently expressed genes in 16 tumors by Affymetrix U133 Plus 2.0 gene array were used to predict AZD0530 sensitivity in an independent group of eight tumors using the K-Top Scoring Pairs (K-TSP) method. "
06/01/2009 - "These data suggest a dominant anti-invasive pharmacology for AZD0530 that may limit tumor progression in a range of cancers. "
04/01/2009 - "Therefore, drugs like AZD0530, designed to inhibit Src activity, could selectively interfere with both tumor and osteoclast activity. "
|1.||Biological Markers (Surrogate Marker)
|8.||dasatinib (BMS 354825)
|1.||Heterologous Transplantation (Xenotransplantation)